<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029418</url>
  </required_header>
  <id_info>
    <org_study_id>09-20-HEP</org_study_id>
    <nct_id>NCT01029418</nct_id>
  </id_info>
  <brief_title>AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a phase I/II clinical trial testing the combination of sorafenib and AZD6244 in
      advanced hepatocellular carcinoma with Childs A liver cirrhosis. The aim of the phase I
      portion is to determine appropriate dose of this drug combination. The phase 2 study will
      look at effectiveness and safety of this drug combination
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with unresectable BCLC Stage B/C hepatocellular carcinoma that is biopsy-proven (
      histology or cytology from prior tumor biopsy specimen is acceptable Patients without prior
      systemic treatment ( chemotherapy or molecular targeted therapy) except prior adjuvant
      therapy, if given more than 6 months ago Child-Pugh class A only ECOG performance status 0 or
      1
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The phase II portion was not conducted due to funding issue.
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of AZD6244 and sorafenib in patients with advanced hepatocellular cancer.</measure>
    <time_frame>12-15months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate if the combination sorafenib and AZD6244 increases Time To Progression (TTP) over sorafenib alone in patients with advanced hepatocellular carcinoma patients.</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AZD6244 and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD6244+ sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244 and sorafenib</intervention_name>
    <description>dose escalation of AZD6244; sorafenib 400mg bd</description>
    <arm_group_label>AZD6244 and sorafenib</arm_group_label>
    <other_name>AZD6244,</other_name>
    <other_name>MEK inhibitor,</other_name>
    <other_name>sorafenib,</other_name>
    <other_name>Raf kinase inhibitor</other_name>
    <other_name>nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unresectable BCLC Stage B/C hepatocellular carcinoma that is
             biopsy-proven ( histology or cytology from prior tumor biopsy specimen is acceptable)

          -  Patients without prior systemic treatment ( chemotherapy or molecular targeted
             therapy) except prior adjuvant therapy, if given more than 6 months ago

          -  Patients who had prior local therapy ( TACE; PEI; RFA) more than 4 weeks prior to
             study entry

          -  No radiotherapy within 4 weeks before entry

          -  Child-Pugh class A only ( Appendix A)

          -  Age 21 years and older

          -  ECOG performance status 0 or 1 ( Appendix A)

          -  Life expectancy &gt; 3 months.

          -  Patients must have normal organ and marrow function as defined below:

        Absolute neutrophil count &gt; 1.5 x 109/L;Platelets&gt; 75 x 109/L; Haemoglobin &gt; 9.0g/dl;Total
        bilirubin &lt; 51umol/L ( 3 mg /dL); AST(SGOT)/ALT(SGPT) &lt; 5 X institutional ULN; Creatinine
        1.5 ULN; INR &lt;1.7 or prothrombin time ( PT) &lt;4 seconds above ULN; Left ventricular ejection
        fraction (LVEF) &gt;50%

          -  Measurable disease according to RECIST. A lesion which has previously been locally
             treated (including TACE or RFA) is eligible as long as there is evidence of disease
             progression

          -  Suitable for oral administration of drug

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior systemic therapy including sorafenib or a MEK inhibitor or sunitinib or other
             investigational drugs

          -  Any prior local therapy ( surgery, radiation therapy, hepatic arterial embolization,
             or cryoablation) within 4 weeks of study entry.

          -  Prior liver transplant

          -  NCI CTCAE grade &gt; 3 hemorrhage within 4 weeks of starting study treatment, or
             documented variceal hemorrhage of any grade within 12 months of study entry (as
             documented on endoscopy)

          -  Presence of esophageal varices (&gt; Grade 2) at risk of bleeding and/or serious or
             non-healing wound/ulcer ( as documented by endoscopy)

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 28 days of study entry

          -  Patients with underlying inflammatory bowel disease, partial or complete bowel
             obstruction or chronic diarrhea

          -  Any of the following within the 12 months prior to study drug administration:
             severe/unstable angina, myocardial infarction, coronary artery bypass graft,
             symptomatic congestive heart failure, cerebrovascular accident, including transient
             ischemic attack, or pulmonary embolism.

          -  History of cardiac disease:

          -  active congestive heart failure

          -  cardiac arrythmias of NCI CTCAE grade &gt;2 or requiring pacemaker

          -  uncontrolled hypertension

          -  cardiomyopathy

          -  atrial fibrillation rate &gt;100bpm

          -  Patients with factors that increase the risk of QT prolongation or arrhythmic events (
             hypokalemia, family history of long QT interval syndrome) or QTc interval of &gt; 450ms
             for males or &gt; 470ms for females on screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Pin Choo</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol. 2010 Jan;52(1):79-87. doi: 10.1016/j.jhep.2009.10.008. Epub 2009 Oct 28.</citation>
    <PMID>19910069</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Centre, Singapore</investigator_affiliation>
    <investigator_full_name>Choo Su Pin</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

